Search - tctmd.com

Displaying 201 - 220 of 334

Sort: Relevancy | Date

News Daily News

Evidence Supporting Percutaneous or Surgical LAA Exclusion for Stroke Prevention Is Limited, Review Says

July 14, 2016

News Daily News

Sigue Abusándose de la Aspirina como Protección Única frente a los ACV en Pacientes con FA

June 27, 2016

News Daily News

Aspirin as Standalone Stroke Protection Still Overused for Patients With A-fib

June 27, 2016

News Conference News TVT 2016

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

Michael O'Riordan

June 18, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2016

April 29, 2016

News Daily News

现实世界研究在很大程度上证实了阿哌沙班和利伐沙班对房颤的影响。

April 21, 2016

News Daily News

Un Estudio del Mundo Real Confirma los Efectos de Apixaban y Rivaroxaban en el Manejo de la FA

April 21, 2016

News Daily News

Real-World Study Largely Confirms Effects of Apixaban, Rivaroxaban for A-fib

April 21, 2016

News Conference News ACC 2016

Comparing the Novel Oral Anticoagulants: Effectiveness Similar, but Apixaban May Come With Less Bleeding

April 06, 2016

News Daily News

Nuevos Roles de las Clínicas Especializadas en Anticoagulación en una Era de Opciones Sin Warfarina

March 01, 2016

News Daily News

New Roles for Anticoagulation Clinics in an Era of Non-Warfarin Options

March 01, 2016

News Conference News ISC 2016

To Anticoagulate or Not? Debating Secondary Stroke Prevention in an A-fib Patient With Microbleeds

Michael O'Riordan

February 23, 2016

News Daily News

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Yael L. Maxwell

December 14, 2015

News Conference News AHA 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Yael L. Maxwell

November 10, 2015

News Daily News

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

October 26, 2015

News Daily News

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

October 26, 2015

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presentation TCT 2015

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Pascal Vranckx, Renato D. Lopes

October 14, 2015

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

Presentation TCT 2015

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

Presenter: Lisa K. Jennings, Matthew T. Roe

October 14, 2015

News Industry News

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

September 16, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.